B+
Bull case
25%
Probability
Target price
$18.50
+50.8% vs current
RGNX
REGENXBIOANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$10.50
-14.4% vs current
B-
Bear case
25%
Probability
Target price
$6.50
-47.0% vs current
AI sentiment snapshot
Latest data as of 2026-07-17
Recent news sentiment (30D)
-0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+61.9
Score
AI commentary
Primary-source evidence is strong, but the thesis remains cautious and monitoring-oriented. Recent headlines indicate elevated attention, including a reported after-hours selloff, but the packet lacks a verified price-reaction series, options data, short-interest data, social coverage, and analyst revisions. Missing data is not treated as positive evidence.
RankAlpha Sentiment Codex - 2026-07-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-31eventAbbVie milestone receiptHigh impact
Milestone payment tied to first-patient dosing in the Phase IIb/III diabetic-retinopathy trial is expected in July 2026, supporting near-term cash runway. [#8-K-2026-06-29]
2026-11-15eventWet AMD pivotal topline dataHigh impact
The company expects pivotal topline data for subretinal wet AMD in Q4 2026, creating a material binary test of the AbbVie-partnered retinal platform. [#SEC-8K-2026-05-14]
2027-12-31catalystRGX-202 regulatory progressionHigh impact
Positive AFFINITY DUCHENNE Phase III topline results support the company’s plans toward a potential 2027 approval, but regulatory path and durability remain execution risks. [#SEC-8K-2026-05-14]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology